Susan Jones‐Bolin

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Mark J. Levis, Jeffrey Allebach, Kam-Fai Tse et al. · Blood · 2002 · 469 citations

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

Roberto Piva, Bruce Ruggeri, Michael Williams et al. · Blood · 2007 · 252 citations · Full text

Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist

Paweł Dobrzański, Kathryn Hunter, Susan Jones‐Bolin et al. · Cancer Research · 2004 · 159 citations

CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.

Christopher J. Strock, Jong‐In Park, Mark Rosen et al. · PubMed · 2003 · 94 citations

Pathology, Cancer Biology, Tumor Biology +17

Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E

Martin W. Rowbottom, Raffaella Faraoni, Qi Chao et al. · Journal of Medicinal Chemistry · 2011 · 58 citations · Full text

Orally Efficacious Inhibitor, Chemoprevention Strategy, Immunology +19